Ziltivekimab Fails to Reduce Cardiovascular Events Despite Lowering Inflammatory Markers
The ZEUS trial confirms ziltivekimab successfully reduces IL-6 but fails to improve clinical outcomes.
1ZEUS Trial Primary Results
The ZEUS trial evaluated ziltivekimab, a monoclonal antibody targeting the IL-6 ligand, in patients with atherosclerotic cardiovascular disease and chronic kidney disease. Over a median follow-up of 33 months, the study found no significant reduction in primary composite endpoints, including cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, compared to placebo.
2Biomarker Reduction Success
Despite the neutral clinical outcomes, the drug demonstrated significant efficacy in reducing inflammatory markers. Ziltivekimab achieved a 76% placebo-adjusted reduction in free interleukin-6 and a 64% reduction in high-sensitivity C-reactive protein. These results confirm that while the drug successfully modulates inflammatory pathways, this biological change did not translate into cardiovascular protection.
3Advanced Disease Progression
Researchers suggest the trial population may have had overly advanced disease, potentially limiting the therapeutic window. Compared to previous successful anti-inflammatory studies like CANTOS, ZEUS participants had higher rates of diabetes, heart failure, and chronic kidney disease. This suggests that late-stage, non-modifiable disease may be less responsive to short-term anti-inflammatory interventions.
4Genetic Versus Therapeutic Causality
The trial highlights a distinction between genetic causality and therapeutic reversibility. While Mendelian randomization studies previously indicated that IL-6 levels are in the causal pathway for cardiovascular risk, the ZEUS results prove that lowering these levels later in life does not necessarily reverse established clinical damage in high-risk, multi-morbid patient populations.
5Broader Clinical Trial Impact
Following the ZEUS findings, Novo Nordisk halted two additional trials, HERMES and ATHENA, due to futility. However, the ARTEMIS trial, which focuses on patients with acute coronary ischemia, remains active. These developments underscore the complexity of the NLRP3 to IL-1 to IL-6 inflammatory pathway and the ongoing search for effective therapeutic strategies.
6Comparison With Previous Studies
The results contrast with earlier trials like CANTOS, LoDoCo2, and COLCOT, which demonstrated that anti-inflammatory therapies can reduce event rates in stable coronary disease. Experts note that these differences may stem from the specific patient populations selected, suggesting that future research must better identify which drug works for which specific patient group.
7Future Research Directions
Moving forward, investigators are looking toward upstream targets, specifically the NLRP3 inflammasome, for which orally available agents are currently in development. Experts emphasize that the failure of ziltivekimab does not mean inflammation is irrelevant, but rather highlights the need for more precise, mechanistic studies to address residual inflammatory risk in cardiovascular patients.
8Clinical Takeaways for Physicians
Clinicians are encouraged to continue managing inflammation through established methods, including diet, exercise, smoking cessation, and existing therapies like statins or GLP-1 drugs. While ziltivekimab did not meet its primary endpoint, the trial provides critical data on the biology of atherosclerosis, reinforcing the necessity for rigorous scientific inquiry into complex inflammatory mechanisms.